Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: Diversified Electronics
- Sub-Industry: N/A
- Symbol: VTX:ROG
- CUSIP: N/A
- Web: www.roche.com
- 50 Day Moving Avg: CHF 118.88
- 200 Day Moving Avg: CHF 105.01
- Trailing P/E Ratio: 30.84
- P/E Growth: 1.49
- Net Margins: 21.17%
- Return on Equity: 46.76%
- Return on Assets: 14.96%
Frequently Asked Questions for Roche Holding (VTX:ROG)
What is Roche Holding's stock symbol?
Roche Holding trades on the VTX under the ticker symbol "ROG."
Where is Roche Holding's stock going? Where will Roche Holding's stock price be in 2017?
15 brokerages have issued 12-month price targets for Roche Holding's shares. Their predictions range from CHF 210 to CHF 325. On average, they expect Roche Holding's stock price to reach CHF 268.07 in the next year. View Analyst Ratings for Roche Holding.
Who are some of Roche Holding's key competitors?
Some companies that are related to Roche Holding include Partnership Assurance Group PLC (PA), GlaxoSmithKline plc (GSK), AstraZeneca plc (AZN), Shire PLC (SHP), Illumina (ILMN), Hospira (HSP), Smith & Nephew plc (SN), Omnicare (OCR), Bio-Rad Laboratories (BIO), Valeant Pharmaceuticals Intl (VRX), NMC Health PLC (NMC), ConvaTec Group PLC (CTEC), Health Net (HNT), Patheon NV (PTHN), Mediclinic International PLC (MDC), Catalent (CTLT), Puma Biotechnology (PBYI) and WuXi PharmaTech (Cayman) (WX).
Who are Roche Holding's key executives?
MarketBeat Community Rating for Roche Holding (VTX ROG)MarketBeat's community ratings are surveys of what our community members think about Roche Holding and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Roche Holding's management team includes the folowing people:
- Severin Schwan, Chairman of the Corporate Executive Committee, Chief Executive Officer, Executive Director
- Alan Hippe, Member of the Corporate Executive Committee, Chief Financial Officer, Information Technology Officer
- Stephan Feldhaus, Member of the Enlarged Corporate Executive Committee, Head Group Communications
- Sophie Kornowski-Bonnet, Member of the Enlarged Corporate Executive Committee, Head Roche Partnering
- Osamu Nagayama, Member of the Enlarged Corporate Executive Committee, Chairman and Chief Executive Officer Chugai
- John C. Reed M.D., Ph.D., Member of the Enlarged Corporate Executive Committee, Head of Roche Pharma Research & Early Development
- Michael David Varney, Member of the Enlarged Corporate Executive Committee, Head Genetech Research and Early Development
- Cristina A. Wilbur, Member of the Executive Committee, Head Group Human Resources
- Urs Jaisli, Chief Compliance Officer
- Gottlieb A. Keller, Member of the Group Executive Committee, General Counsel, Secretary to the Board of Directors
Consensus Ratings for Roche Holding (VTX:ROG) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||1 Sell Rating, 6 Hold Ratings, 8 Buy Ratings|
|Consensus Rating:||Hold (Score: 2.47)|
|Consensus Price Target: ||CHF 268.07|
Analysts' Ratings History for Roche Holding (VTX:ROG)
(Data available from 9/20/2015 forward)
|9/18/2017||HSBC Holdings plc||Set Price Target||Sell||CHF 210|
|9/13/2017||Barclays PLC||Set Price Target||Buy||CHF 295|
|9/12/2017||Baader Bank||Set Price Target||Neutral||CHF 231|
|9/11/2017||J P Morgan Chase & Co||Reiterated Rating||Buy|
|9/11/2017||Deutsche Bank AG||Set Price Target||Neutral||CHF 255|
|9/11/2017||Credit Suisse Group||Set Price Target||Buy||CHF 300|
|9/11/2017||Kepler Capital Markets||Set Price Target||Neutral||CHF 230|
|9/11/2017||Goldman Sachs Group, Inc. (The)||Set Price Target||Buy||CHF 325|
|8/15/2017||Berenberg Bank||Set Price Target||Buy||CHF 273|
|7/27/2017||Sanford C. Bernstein||Set Price Target||Buy||CHF 284|
|7/26/2017||Morgan Stanley||Set Price Target||Neutral||CHF 260|
|7/12/2017||Jefferies Group LLC||Set Price Target||Buy||CHF 275|
|7/5/2017||Citigroup Inc.||Reiterated Rating||Buy|
|6/29/2017||Societe Generale||Set Price Target||Neutral||CHF 275|
|6/20/2017||BNP Paribas||Set Price Target||Neutral||CHF 250|
Earnings History for Roche Holding (VTX:ROG)
No earnings announcements for this company have been tracked by MarketBeat.com
Earnings Estimates for Roche Holding (VTX:ROG)
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for Roche Holding (VTX:ROG)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for Roche Holding (VTX:ROG)
No insider trades for this company have been tracked by MarketBeat.com
Headline Trends for Roche Holding (VTX:ROG)
Latest Headlines for Roche Holding (VTX:ROG)